Wenzhi Tian, MD

The founder, chairman, CEO and CSO, Dr. Wenzhi Tian, EMBA, is a renowned expert in cancer immunotherapies. Dr. Tian has over 30 years of academic and industrial experience in the field of immuno-oncology. Based on his in-depth understanding of cancer immunology, Dr. Tian has been at the forefront of scientific research and built a proven track record in target validation, molecule design and drug development for immunotherapies. He identified CD47 as a promising immunotherapeutic target and commenced drug research on CD47 starting from 2010, roughly 10 years earlier than the validation of CD47 by clinical data. His deep expertise and foresight in target selection also led to our development of multiple monoclonal antibody and bispecific molecules targeting CD24, another promising checkpoint since 2019, all with global first-in-class potential. A prolific scientist, Dr. Tian has 20+ issued patents, 30+ patent applications, and published over 30 scientific papers in the area of immunology and CD47 in internationally-recognized journals.